07:19 AM EDT, 10/27/2026 (MT Newswires) -- Irlab Therapeutics (IRLAB-A.ST) received a notice of allowance from the US Patent and Trademark Office for a patent covering its Parkinson's disease drug candidate IRL1117. The Swedish drug discovery and development company said Tuesday patent 18/858,955, which is expected to remain in force until the early 2040s, will be granted once certain administrative formalities are completed. Irlab is preparing preclinical safety and toxicology studies ahead of the candidate's first clinical trial in humans.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.